Drug profile · INN
linagliptin
TRAJENTA
linagliptin (TRAJENTA) is a dipeptidyl peptidase iv inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — linagliptin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 1
- Programs
- 11
- Data quality
- 0.89
Quick answer
linagliptin (TRAJENTA) is a dipeptidyl peptidase iv inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is linagliptin?
linagliptin (TRAJENTA) is a dipeptidyl peptidase iv inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for linagliptin?
TRAJENTA is a marketed brand name for linagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of linagliptin?
linagliptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.